"I work construction, it takes all the abuse I throw at it." ...

Shares in psychedelic drug developer Compass Pathways are sliding today after it announced that it will slash its headcount by 30% and focus all its efforts on its treatment-resistant depression (TRD) ...

UK biotech Compass Pathways is planning a $100 million US IPO as it seeks to further develop its depression treatment based on psilocybin – an active ingredient that can be found in magic mushrooms.

Stay up to date when the latest road test reports & ratings are released, and get car news, buying advice, maintenance tips and more. Sign up for our FREE weekly Cars Newsletter. Current Model For ...

COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in ...

A video from CGP Grey on how to maximize misery is a helpful way of looking at happiness from a reverse-psychology ...

Watch all your favourite ABC programs on ABC iview. More from ABC We acknowledge Aboriginal and Torres Strait Islander peoples as the First Australians and Traditional Custodians of the lands where we ...

Compass, Inc. engages in the provision of an online real estate platform. Its platform provides an integrated suite of software for customer relationship management, marketing, client service, ...

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed.

Sodexo’s GPO, Entegra, has achieved comparable scale with Compass, increasing the likelihood it can close the margin gap in the near future.